Although the LUME-Lung 1 trial did not evaluate EGFR mutation status, the efficacy of docetaxel and nintedanib in EGFR mutated NSCLC patients has been evaluated in recent clinical trials.20,21. This evidence concerns the gene EGFR and non-small cell lung carcinoma.